Low Back Pain

Probiotic

Inactive capsules

Diagnostic Center

Probiotics for Modic Changes in Low Back Pain Patients

Probiotics for Modic Changes: a Randomised Controlled Study to Elucidate the Effect of Probiotics on Vertebral Inflammatory End-plate Changes, So-called Type 1 Modic Changes

Ole Kudsk Jensen

Consultant, ph.d.

The Danish Rheumatism Association

This is a single-arm study. All subjects will take UDCA and ATRA.

Cholangitis, Sclerosing

The subjects will continue to take their current dose of UDCA (15 mg/kg/day), as per ongoing clinical care, and need to be on a stable dose of UDCA for at least six months prior to enrollment.
The specific intervention is the addition of daily oral ATRA (45 mg/m^2) divided into 2 doses. To increase adherence to the dosing regimen, the drug will be compounded by the Research Pharmacies of Yale and Mayo into 2 formulations (30 mg and 40 mg capsules), and an Investigational New Drug (IND) permit was obtained for this process.

Oral all-trans retinoic acid (ATRA)

Yale University School of Medicine - 333 Cedar St - 1080 LMP

Mayo Clinic

Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis

Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis - A Human Pilot Study

The primary outcome measure is a 30% improvement in serum alkaline phosphatase in subjects, comparing pre- and post-treatment values for each individual.

acne vulgaris/phosphatase

Probiotics for Modic Changes in Low Back Pain Patients

Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus